Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy

Phase 3 Terminated 408 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.

Timeline

Start: 2006-03
Primary completion: 2008-06
Completion: 2008-06

Publications

Allen R, Sharma U, Barlas S. Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. J Pain Res. 2014 Jun 23;7:339-51. doi: 10.2147/JPR.S55682. eCollection 2014.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Desvenlafaxine	Other / unclassified	50 mg	Oral
Subject	Desvenlafaxine	Other / unclassified	100 mg	Oral
Subject	Desvenlafaxine	Other / unclassified	200 mg	Oral
Subject	Desvenlafaxine	Other / unclassified	400 mg	Oral

Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy

Summary

Timeline

Publications

Drugs

Indications